Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
Pancreatic cancer remains a high unmet medical need with limited treatment options. According to the American Cancer Society, about 62,210 will be diagnosed with pancreatic cancer in the United States. in 2022, and more than 49,830 patients will die from the disease -- the highest mortality rate of all major cancers. For advanced disease, chemotherapy (sometimes along with a targeted drug therapy) may lengthen survival.1
- In three of these models, significant changes in tumor growth were observed in those that received QN-302, together with good tolerance and bioavailability at therapeutic doses.
- This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release.
- The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law.
- This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.